ABL1 and nasopharyngeal carcinoma: Moreover, the therapeutic relevance of targeting the c-Abl/TFEB pathway in vivo has been previously demonstrated in the NPC mouse model, where treatment with c-Abl inhibitors Imatinib or GNF2 enhanced TFEB nuclear translocation and reduced cholesterol accumulation in brain tissue [25].